Endometrial Cancer
About the IOV-END-201 trial IOV-END-201 is evaluating whether lifileucel, an investigational TIL cell therapy, can be a new way to fight against advanced endometrial cancer that progressed after prior treatment. The trial is recruiting patients in the U.S. to determine whether lifileucel is safe and can: Patients may be eligible to participate in this trial […]
Advanced Melanoma
About the IOV-IL2-101 trial Patients with previously treated, unresectable, or metastatic melanoma will receive IOV-3001 either before or after lifileucel. The trial will evaluate whether IOV-3001 is safe and determine the best dose. Additionally, it will determine the potential of IOV-3001 to: Patients may be eligible to participate in this trial if they: Visit clinicaltrials.gov […]
Advanced Melanoma
About the TILVANCE-301 trial The TILVANCE-301 trial is currently enrolling patients with melanoma that is untreated, unresectable (cannot be removed by surgery), or metastatic (has spread to a different part of the body). TILVANCE-301 will assess the safety of lifileucel in combination with pembrolizumab and its potential to: Patients may be eligible to participate in […]
Non-Small Cell Lung Cancer (NSCLC)
About the IOV-LUN-202 trial IOV-LUN-202 is a global clinical trial currently enrolling people with NSCLC that has progressed (on previous chemoimmuntherapy) and is metastatic (has spread to a different part of the body). The trial is studying lifileucel, an investigational TIL cell therapy. IOV-LUN-202 will assess the safety of lifileucel and its potential to: Patients […]
